Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyFRA:3NK +0.57%55 Gross Margin % is 86.91% as of Dec. 2025, which is 2% below its 10-year median of 88.78. GuruFocus rates FRA:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.82. The stock has 4 warning signs investors should review. Among 735 Biotechnology companies, Alphamab Oncology ranks better than 82.04% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Alphamab Oncology had a gross margin of 86.91% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Alphamab Oncology Gross Margin % Related Terms
Alphamab Oncology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3NK vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Alphamab Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Alphamab Oncology (FRA:3NK) has a Gross Margin % of 86.91% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Alphamab Oncology and its competitors. This is near median its historical median of 88.78. Over the past decade, Alphamab Oncology's Gross Margin % has ranged from 73.50 to 97.93. According to the industry distribution chart, Alphamab Oncology ranks #132 out of 735 companies in the Biotechnology industry, placing it in the top 18%.
Is Alphamab Oncology's Gross Margin % too high?
Alphamab Oncology's current Gross Margin % of 86.91% is near median its 10-year median of 88.78. Over the past 10 years, this metric has ranged from a low of 73.50 to a high of 97.93. The Biotechnology industry median Gross Margin % is 60.91. Alphamab Oncology's value of 86.91% is 42.7% above this industry median. Based on the distribution chart, Alphamab Oncology ranks #132 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #132 out of 735 companies for Gross Margin %. This places Alphamab Oncology in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Alphamab Oncology's value of 86.91% is 42.7% above this benchmark. Historically, Alphamab Oncology's own Gross Margin % has ranged from 73.50 to 97.93 over the past decade. While the company's 10-year median is 88.78 vs. the industry median of 60.91, Alphamab Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphamab Oncology's current Gross Margin % of 86.91% is 42.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current Gross Margin % is 86.91%, which is near median its own 10-year median of 88.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current Gross Margin % of 86.91%. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current Gross Margin % is 86.91%, which is near median its 10-year median of 88.78 and 42.7% above the Biotechnology industry median of 60.91. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current Gross Margin % is 86.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.
Key valuation signals for FRA:3NK:
Gross Margin %: 86.91% (near median its 10-year median of 88.78)
GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
Industry Position: 42.7% above the Biotechnology median (#132 of 735)
No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for FRA:3NK
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3NK has been successfully added to your 
